Plasma p-tau181 (Phosphorylated Tau at Threonine 181)
📖 Wiki Page
biomarker1095 wordssynced 2026-04-02
Overview
Phosphorylated tau at threonine 181 (p-tau181) is a highly specific blood-based biomarker for Alzheimer's disease pathology. It was one of the first phosphorylated tau species to be developed as a plasma assay and remains widely used in clinical research and increasingly in clinical practice. Plasma p-tau181 correlates with both amyloid-beta and tau pathology as measured by PET imaging, making it a valuable biomarker for detecting Alzheimer-type neurodegeneration.[@palmqvist2020][@janelidze2021]
Pathophysiology
```mermaid flowchart TD %% Blue = Triggers/Inputs A["Amyloid-beta<br/>Oligomers"]:::blue
%% Blue = Outputs F["CSF p-tau181<br/>Elevated"]:::blue
G["Blood-Brain<br/>Barrier"]:::blue
H["Blood p-tau181<br/>Elevated"]:::blue
I{"Diagnostic Interpretation"}:::yellow
J["AD Pathology<br/>Likely"]:::green
K["Consider Non-AD<br/>Etiology"]:::green
L["Systemic<br/>Amyloidosis?"]:::yellow
M["Clinical Diagnosis<br/>AD Supported"]:::green
N["Differential<br/>Diagnosis Workup"]:::blue
O["Additional<br/>Testing"]:::blue
...
Overview
Phosphorylated tau at threonine 181 (p-tau181) is a highly specific blood-based biomarker for Alzheimer's disease pathology. It was one of the first phosphorylated tau species to be developed as a plasma assay and remains widely used in clinical research and increasingly in clinical practice. Plasma p-tau181 correlates with both amyloid-beta and tau pathology as measured by PET imaging, making it a valuable biomarker for detecting Alzheimer-type neurodegeneration.[@palmqvist2020][@janelidze2021]
Pathophysiology
Mermaid diagram (expand to render)
Biological Function
Tau Phosphorylation at Threonine 181
The tau protein (encoded by the MAPT gene) is a microtubule-associated protein that stabilizes neuronal axons. In Alzheimer's disease, tau becomes abnormally hyperphosphorylated, leading to neurofibrillary tangle formation. Threonine 181 is one of the earliest and most studied phosphorylation sites on tau.[@palmqvist2020]
The phosphorylation at position 181 occurs via several kinases, including:
GSK-3β (glycogen synthase kinase-3 beta)
CDK5 (cyclin-dependent kinase 5)
PKA (protein kinase A)
These kinases are activated in Alzheimer's disease by various pathological triggers including amyloid-beta oligomers, neuroinflammation, and mitochondrial dysfunction.
Release into Blood
p-tau181 is released into the cerebrospinal fluid (CSF) and subsequently into blood through:
Axonal degeneration - damaged neurons release tau species into interstitial fluid
Tissue drainage - CSF drains via glymphatic and lymphatic pathways
Blood-brain barrier penetration - tau fragments cross through barrier mechanisms
The phosphorylated form (p-tau181) appears to be more specific to AD pathology than total tau, as it reflects the disease-specific post-translational modifications occurring in AD brains.[@palmqvist2020][@janelidze2021]
Clinical Utility
Alzheimer's Disease Detection
Plasma p-tau181 has demonstrated excellent performance for distinguishing Alzheimer's disease from:
Healthy controls
Other dementias (frontotemporal dementia, vascular dementia)
Other neurodegenerative disorders (Parkinson's disease, Lewy body dementia)
Key performance characteristics:
AUC: 0.85-0.95 for AD vs. controls
Sensitivity: 80-90%
Specificity: 85-95%
Mild Cognitive Impairment (MCI) Prediction
p-tau181 is particularly valuable for predicting progression from MCI to AD dementia:
Elevated p-tau181 in MCI patients predicts progression to AD with high accuracy
Combines well with amyloid-beta 42/40 ratio for enhanced prediction
Can identify AD pathology years before clinical dementia onset
Amyloid and Tau PET Correlation
Plasma p-tau181 correlates with:
Amyloid PET burden (moderate correlation)
Tau PET burden (stronger correlation)
CSF p-tau181 levels (strong correlation)
This makes p-tau181 useful as a screening tool to identify individuals likely to have AD pathology who might benefit from further diagnostic workup or clinical trial enrollment.[@janelidze2021][@karikari2022]
Allows detection of very low concentrations in plasma
ALENTO (Next Generation)
Third-generation immunochemiluminometric assay
Higher sensitivity than previous generations
Improved precision
UCB-MS (Ultrasensitive Immun-MS)
Mass spectrometry-based quantification
High specificity for specific tau phospho-forms
Comparison to Other Tau Biomarkers
| Biomarker | Specificity | Sensitivity (AD) | CSF/Plasma | Key Advantage | |-----------|-------------|------------------|------------|---------------| | p-tau181 | High | 85-90% | Both | First validated, widely available | | p-tau217 | Very High | 90-95% | Both | Best for differential diagnosis | | p-tau231 | High | 80-85% | CSF only | Earliest detection in preclinical AD | | Total tau | Moderate | 70-80% | Both | Non-specific neuronal damage |
p-tau181 vs p-tau217
p-tau217 shows slightly better performance for distinguishing AD from other neurodegenerative diseases
p-tau181 was the first to be widely validated and has more established clinical data
Both correlate well with tau PET and predict cognitive decline
p-tau217 may be slightly better for detecting early/mild AD
p-tau181 in Non-AD Conditions
Recent research (2026) has revealed that p-tau181 can also be elevated in systemic amyloidoses:[@elevated2026]
This finding has important implications for differential diagnosis in patients with both AD and systemic amyloidosis, as well as for clinical trial interpretation.
p-tau181 in 4R Tauopathies
Corticobasal Degeneration (CBD)
In corticobasal syndrome (CBS), plasma p-tau181 helps distinguish:[@altmann2025][@stamelou2023]
CBS due to CBD: p-tau181 typically normal or mildly elevated
CBS due to AD: p-tau181 markedly elevated, similar to AD levels
The p-tau181/NfL ratio has emerged as a useful discriminator between AD and 4R tauopathies.
Progressive Supranuclear Palsy (PSP)
In PSP, p-tau181 shows:
Mild to moderate elevation compared to healthy controls
Lower levels than AD but higher than Parkinson's disease
When combined with NfL, can help distinguish PSP from other parkinsonisms
Clinical Implementation
Interpretation Guidelines
p-tau181 should be interpreted in clinical context:
Elevated p-tau181 + clinical symptoms → supports AD diagnosis
Normal p-tau181 + clinical symptoms → consider non-AD etiology